Citryll doses first subject in Phase IIa trial of monoclonal antibody for RA
The study plans to recruit 88 subjects who will participate in a treatment period for six weeks.
Medical Devices
AAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s disease
Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
Glucotrack hits trial success for direct blood measuring CGM
Tivic hits enrolment target for vagus nerve stimulation trial
Intelligent gears up for FDA approval of fingerprint drug detection device
Sinaptica’s neuromodulation device aces Phase II Alzheimer’s trial
Nexalin trials Halo neurostimulation device in traumatic brain injury
